http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PT-92166-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa48a431ce250933eb0fdd7a1caf3f30
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B09B2101-68
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B09B3-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
filingDate 1989-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1995-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PT-92166-B
titleOfInvention METHOD OF PREPARING A DOSAGE FORM WITH A REDUCED POTENTIAL OF DRUG ABUSE
abstract Compositions and dosage forms for administering abusable substances are disclosed which have a reduced potential for abuse without diminishing the therapeutic or beneficial effects of the abusable substance. Topical compositions for application to the skin or mucosa contain the abusable substance in a form which is permeable to the skin or mucosa to which it is to be applied and an antagonist for the abusable substance is present in the composition in an abuse negating amount and in a form that is impermeable to the skin or mucosa to which the composition is to be applied. Controlled release dosage forms which release the abusable substance from a drug reservoir composition confined behind a release rate controlling barrier have the abusable substance and its antagonist in the drug reservoir. The abusable substance is present in a form that is releasable from the dosage form and the antagonist is present in an abuse negating amount in a form that is not releasable from the dosage form. Thus the compositions and dosage forms of this invention permit the therapeutic use, at substantially full potency, of an abusable substance when use as prescribed but reduce the abuse potential of the compositions and dosage forms by other routes of administration. Preferred embodiments of the invention utilize fentanyl as the abusable substance and naltrexone as the antagonist in a transdermal dosage form.
priorityDate 1988-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505409
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501369
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13810
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID51263
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590451
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284596
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507785
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284569
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494086
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10070040
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5360515
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4058
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507804
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3345
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416053110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284595
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535661
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414857871
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426326933
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284603
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533539
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4095
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493286
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10100
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID446220
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419500907
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311304
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507675
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9848990
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494211
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493221
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507064
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552989
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505278
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4736
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555047
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41693
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5361092
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449812066
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284604
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644017
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30131
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507876

Total number of triples: 71.